Private company

Notable Labs, Ltd.

Pharmaceutical preparations company. Summary from the record

Last updated Oct 19, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersFoster City, California1
  • Incorporated inIsrael2
  • Business address320 Hatch Drive, Foster City, Ca 944042
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Notable continuing after the merger as the surviving entity and a wholly owned subsidiary of the Company (the “Merger”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

36.5%Gross margin4
-4728.1%Operating margin4
-3633.5%Net margin4
3775.0%Revenue growth, 20234
-74.5%Return on equity4
-$13.8MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue4¢$197.0K
  • Research and development96¢$4.7M

Out of $310.0K in revenue.4 The company lost money this year.

Financial statements

Revenue56784$310.0K in 2023−98% since 2017
0$5.0M$10.0M$15.0M2017: $13.9M$13.9M20172018: $585.0K$585.0K2018−96%2019: $562.0K$562.0K2019−4%2020: $922.0K$922.0K2020+64%2021: $768.0K$768.0K2021−17%2022: $8.0K$8.0K2022−99%2023: $310.0K$310.0K2023+3775%
Gross profit56784$113.0K in 2023−99% since 2017
0$5.0M$10.0M$15.0M2017: $13.5M$13.5M20172018: $330.0K$330.0K2018−98%2019: $340.0K$340.0K2019+3%2020: $528.0K$528.0K2020+55%2021: $403.0K$403.0K2021−24%2022: $8.0K$8.0K2022−98%2023: $113.0K$113.0K2023+1312%
Operating income56784-$14.7M in 2023
-$40.0M-$20.0M0$20.0M$40.0M2017: $10.1M$10.1M20172018: $21.2M$21.2M2018+110%2019: -$20.1M-$20.1M20192020: -$24.5M-$24.5M2020+22%2021: -$30.0M-$30.0M2021+23%2022: -$12.9M-$12.9M2022−57%2023: -$14.7M-$14.7M2023+13%
Net income6784-$11.3M in 2023
-$40.0M-$20.0M0$20.0M$40.0M2018: $20.5M$20.5M20182019: -$19.4M-$19.4M20192020: -$24.2M-$24.2M2020+25%2021: -$29.9M-$29.9M2021+24%2022: -$14.4M-$14.4M2022−52%2023: -$11.3M-$11.3M2023−22%
Fiscal year2017201820192020202120222023
Revenue$13.9M5$585.0K6$562.0K7$922.0K7$768.0K8$8.0K4$310.0K4
Cost of revenue$255.0K6$222.0K7$394.0K7$365.0K8$104.0K8$197.0K4
Gross profit$13.5M5$330.0K6$340.0K7$528.0K7$403.0K8$8.0K4$113.0K4
Research and development$15.2M6$14.7M7$19.7M7$22.7M8$7.8M4$4.7M4
Operating expenses$12.9M4$14.8M4
Operating income$10.1M5$21.2M6-$20.1M7-$24.5M7-$30.0M8-$12.9M4-$14.7M4
Interest$159.0K6$184.0K7$105.0K7$44.0K8$85.0K8
Net income$20.5M6-$19.4M7-$24.2M7-$29.9M8-$14.4M4-$11.3M4
Earnings per share$0.458-$21.974-$3.414
Earnings per share (diluted)-$21.974-$3.414
Shares (weighted, basic)66.3M shares8655.7K shares43.3M shares4
Shares (weighted, diluted)655.7K shares43.3M shares4

Compare Notable Labs, Ltd. with another company

Leadership

Who has led Notable Labs, Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dror Harats2023
  2. Thomas Bock2023–2024
  3. Kaile A. Zagger2024

Chief financial officer

  1. Samuel Backenroth2023
  2. Scott Alan McPherson2023
2025
Board members and other officers (13)

Former names

  • Vascular Biogenics Ltd.Mar 25, 2014 to Oct 12, 20232

Timeline

  1. Sep 26, 2024New chief executive Kaile A. Zagger becomes CEO13
  2. Oct 18, 2023New chief executive Thomas Bock becomes CEO15
  3. Jan 3, 2023New chief executive Dror Harats becomes CEO14

Filings

157 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 37 major events, 37 insider forms, 8 large holders, 67 other. The latest 20:

  1. Aug 18, 2025SEC STAFF ACTION EDGAR
  2. Oct 16, 20248-K EDGAR
  3. Oct 15, 20248-K EDGAR
  4. Sep 26, 20243 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  5. Sep 19, 20248-K EDGAR
  6. Sep 16, 20248-K EDGAR
  7. Aug 29, 2024S-1/A EDGAR
  8. Aug 26, 2024S-1/A EDGAR
  9. Aug 26, 20248-K EDGAR
  10. Aug 14, 202410-Q EDGAR
  11. Aug 9, 2024SC 13D/A EDGAR
  12. Aug 6, 20248-K EDGAR
  13. Jul 24, 20248-K EDGAR
  14. Jul 19, 20248-K EDGAR
  15. Jul 1, 2024S-1/A EDGAR
  16. Jun 20, 2024S-1 EDGAR
  17. May 30, 20248-K EDGAR
  18. May 15, 202410-Q EDGAR
  19. May 10, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. May 10, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 157 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 0 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 2, 2024FR Capital Holdings, L.P.Sale50,000$1.89$94.5KForm 4
Dec 29, 2023FR Capital Holdings, L.P.Sale6,000$1.83$11.0KForm 4
Dec 28, 2023FR Capital Holdings, L.P.Sale21,500$2.01$43.2KForm 4
Dec 27, 2023FR Capital Holdings, L.P.Sale20,033$2.08$41.7KForm 4
Dec 26, 2023FR Capital Holdings, L.P.Sale11,456$2.16$24.7KForm 4
Dec 22, 2023FR Capital Holdings, L.P.Sale45,000$2.41$108.5KForm 4
Dec 21, 2023FR Capital Holdings, L.P.Sale2,867$2.51$7.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35